ASX Announcement

27 June 2023

MHRA Approval Received to Conduct Phase IIb Trial in the UK for ATL1102 in DMD

Key Highlights:

- Regulatory approvals in all four countries (UK, Turkey, Bulgaria and Australia) to conduct the Phase IIb trial.
- Three patients have now received a first dose.

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] (ANP or Company) today announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during Q3'CY2023.

"We now have regulatory approvals in all four countries where the study will be conducted and are looking forward to commencing activities in the UK where we intend to open multiple clinical sites to advance patient enrolment." said Dr Charmaine Gittleson, Antisense Board Chair. "We are further encouraged by the fact that three patients have already received their first dose."

In parallel with commencement of the trial, the Company is pleased to be enhancing its patient advocacy interactions with Dr Gil Price's participation in the upcoming Parent Project Muscular Dystrophy (PPMD) 9th annual conference (29 June to 1 July 2023; https://web.cvent.com/event/f695ea28-c338-4307-bbd3-c5b27a9fae3e/summary) where he will present on ATL1102 and the Phase IIb study.

For more information please contact:

Antisense Therapeutics
Charmaine Gittleson
Executive Chair
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

US/European IR & Media
Laine Yonker/Joe Green
Edison Investor Relations
lyonker@edisongroup.com
+1 646-653-7035

This announcement has been authorised for release by the Executive Chair.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial.

About ATL1102 Phase IIb trial in DMD The trial is a two-part design to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ATL1102. Participants will be enrolled and randomised to receive either ATL1102 (25mg dose), ATL1102 (50mg dose) or matched placebo in a 1:1:1 ratio given as a weekly subcutaneous injection for a 24-week randomized, double-blind, placebo-controlled treatment period (Part A). Efficacy and safety data will be assessed at the end of Part A. Participants will then continue to the Open Label Extension treatment period (Part B) and continue to receive ATL1102 (25mg or 50mg dose) for a further 24 weeks. Participants on placebo in Part A will cross over to receive ATL1102 in Part B. A four month follow up period occurs after Part B.